{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:28:51Z","timestamp":1791124131416,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T00:00:00Z","timestamp":1215734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00262-008-0559-5","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T08:56:23Z","timestamp":1215680183000},"page":"361-371","source":"Crossref","is-referenced-by-count":11,"title":["TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis"],"prefix":"10.1007","volume":"58","author":[{"given":"Roghieh","family":"Djafarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"von Luettichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra S.","family":"Skrablin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Noessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,11]]},"reference":[{"issue":"3","key":"559_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161\u2013174","journal-title":"Nat Rev Cancer"},{"key":"559_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bse0380021","volume":"38","author":"Y Itoh","year":"2002","unstructured":"Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. Essays Biochem 38:21\u201336","journal-title":"Essays Biochem"},{"issue":"6","key":"559_CR3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/BC.2003.097","volume":"384","author":"W Bode","year":"2003","unstructured":"Bode W, Maskos K (2003) Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 384(6):863\u2013872","journal-title":"Biol Chem"},{"issue":"31","key":"559_CR4","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","volume":"274","author":"H Nagase","year":"1999","unstructured":"Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274(31):21491\u201321494","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"559_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-4838(99)00279-4","volume":"1477","author":"K Brew","year":"2000","unstructured":"Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1\u20132):267\u2013283","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"559_CR6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1515\/BC.2001.173","volume":"382","author":"CM Klier","year":"2001","unstructured":"Klier CM, Nelson EL, Cohen CD, Horuk R, Schlondorff D, Nelson PJ (2001) Chemokine-induced secretion of gelatinase B in primary human monocytes. Biol Chem 382(9):1405\u20131410","journal-title":"Biol Chem"},{"issue":"14","key":"559_CR7","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1158\/1078-0432.CCR-07-0186","volume":"13","author":"NM Sorensen","year":"2007","unstructured":"Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, Glimelius B (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13(14):4117\u20134122","journal-title":"Clin Cancer Res"},{"issue":"2","key":"559_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/1566523024605564","volume":"2","author":"K Brand","year":"2002","unstructured":"Brand K (2002) Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2(2):255\u2013271","journal-title":"Curr Gene Ther"},{"issue":"1","key":"559_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10555-006-7893-x","volume":"25","author":"R Chirco","year":"2006","unstructured":"Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1):99\u2013113","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"559_CR10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1096\/fasebj.10.5.8621057","volume":"10","author":"ME Medof","year":"1996","unstructured":"Medof ME, Nagarajan S, Tykocinski ML (1996) Cell-surface engineering with GPI-anchored proteins. FASEB J 10(5):574\u2013586","journal-title":"FASEB J"},{"issue":"7","key":"559_CR11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1515\/BC.2004.081","volume":"385","author":"R Djafarzadeh","year":"2004","unstructured":"Djafarzadeh R, Mojaat A, Vicente AB, von Luttichau I, Nelson PJ (2004) Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities. Biol Chem 385(7):655\u2013663","journal-title":"Biol Chem"},{"issue":"10","key":"559_CR12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.onc.1209188","volume":"25","author":"R Djafarzadeh","year":"2006","unstructured":"Djafarzadeh R, Noessner E, Engelmann H, Schendel DJ, Notohamiprodjo M, von Luettichau I, Nelson PJ (2006) GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 25(10):1496\u20131508","journal-title":"Oncogene"},{"issue":"22","key":"559_CR13","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/sj.gt.3301325","volume":"7","author":"O Brown","year":"2000","unstructured":"Brown O, Cowen RL, Preston CM, Castro MG, Lowenstein PR (2000) Subcellular post-transcriptional targeting: delivery of an intracellular protein to the extracellular leaflet of the plasma membrane using a glycosyl-phosphatidylinositol (GPI) membrane anchor in neurons and polarised epithelial cells. Gene Ther 7(22):1947\u20131953","journal-title":"Gene Ther"},{"issue":"2","key":"559_CR14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CMR.0b013e328042bb36","volume":"17","author":"C Garbe","year":"2007","unstructured":"Garbe C, Eigentler TK (2007) Diagnosis, treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17(2):117\u2013127","journal-title":"Melanoma Res"},{"issue":"4","key":"559_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/092986707779941078","volume":"14","author":"CA La Porta","year":"2007","unstructured":"La Porta CA (2007) Drug resistance in melanoma: new perspectives. Curr Med Chem 14(4):387\u2013391","journal-title":"Curr Med Chem"},{"issue":"5","key":"559_CR16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/B:APPT.0000038036.31271.50","volume":"9","author":"F Facchetti","year":"2004","unstructured":"Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA (2004) Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9(5):573\u2013582","journal-title":"Apoptosis"},{"issue":"20","key":"559_CR17","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22(20):3138\u20133151","journal-title":"Oncogene"},{"issue":"8949","key":"559_CR18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(95)90463-8","volume":"345","author":"J Overgaard","year":"1995","unstructured":"Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345(8949):540\u2013543","journal-title":"Lancet"},{"issue":"9210","key":"559_CR19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(00)02059-6","volume":"355","author":"J Zee van der","year":"2000","unstructured":"van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355(9210):1119\u20131125","journal-title":"Lancet"},{"issue":"13","key":"559_CR20","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1200\/JCO.2005.05.520","volume":"23","author":"EL Jones","year":"2005","unstructured":"Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW (2005) Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 23(13):3079\u20133085","journal-title":"J Clin Oncol"},{"issue":"3","key":"559_CR21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11864-004-0009-3","volume":"5","author":"DL Fraker","year":"2004","unstructured":"Fraker DL (2004) Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 5(3):173\u2013184","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"559_CR22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.sla.0000251746.02764.fc","volume":"245","author":"A Sanki","year":"2007","unstructured":"Sanki A, Kam PC, Thompson JF (2007) Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 245(4):591\u2013596","journal-title":"Ann Surg"},{"issue":"3","key":"559_CR23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/02656730500532028","volume":"22","author":"HH Kampinga","year":"2006","unstructured":"Kampinga HH (2006) Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia 22(3):191\u2013196","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"559_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxh203","volume":"17","author":"V Milani","year":"2005","unstructured":"Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, Issels RD, Noessner E (2005) Melanoma-associated antigen tyrosinase but not Melan-A\/MART-1 expression and presentation dissociate during the heat shock response. Int Immunol 17(3):257\u2013268","journal-title":"Int Immunol"},{"issue":"14","key":"559_CR25","first-page":"3149","volume":"55","author":"L Rivoltini","year":"1995","unstructured":"Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA et al (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55(14):3149\u20133157","journal-title":"Cancer Res"},{"issue":"1","key":"559_CR26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/bbrc.1995.2275","volume":"214","author":"AC Kirby","year":"1995","unstructured":"Kirby AC, Hill V, Olsen I, Porter SR (1995) LFA-3 delta D2: a novel in vivo isoform of lymphocyte function-associated antigen 3. Biochem Biophys Res Commun 214(1):200\u2013205","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"559_CR27","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92(15):7021\u20137025","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"559_CR28","first-page":"3248","volume":"39","author":"J Overgaard","year":"1979","unstructured":"Overgaard J, Suit HD (1979) Time-temperature relationship the hyperthermic treatment of malignant and normal tissue in vivo. Cancer Res 39(8):3248\u20133253","journal-title":"Cancer Res"},{"key":"559_CR29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0076-6879(90)86169-V","volume":"186","author":"RD Issels","year":"1990","unstructured":"Issels RD, Nagele A (1990) Influence of thiols on thermosensitivity of mammalian cells in vitro. Methods Enzymol 186:696\u2013708","journal-title":"Methods Enzymol"},{"issue":"3","key":"559_CR30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/hyb.1997.16.217","volume":"16","author":"RF Schwabe","year":"1997","unstructured":"Schwabe RF, Hess S, Johnson JP, Engelmann H (1997) Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Hybridoma 16(3):217\u2013226","journal-title":"Hybridoma"},{"issue":"10","key":"559_CR31","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.4049\/jimmunol.169.10.5424","volume":"169","author":"E Noessner","year":"2002","unstructured":"Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD (2002) Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 169(10):5424\u20135432","journal-title":"J Immunol"},{"issue":"3","key":"559_CR32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/0265673031000119006","volume":"19","author":"MW Dewhirst","year":"2003","unstructured":"Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ (2003) Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 19(3):267\u2013294","journal-title":"Int J Hyperthermia"},{"issue":"6","key":"559_CR33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ijc.22450","volume":"120","author":"HM Ko","year":"2007","unstructured":"Ko HM, Kang JH, Jung B, Kim HA, Park SJ, Kim KJ, Kang YR, Lee HK, Im SY (2007) Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis. Int J Cancer 120(6):1277\u20131283","journal-title":"Int J Cancer"},{"issue":"4","key":"559_CR34","first-page":"609","volume":"18","author":"XJ Qu","year":"2006","unstructured":"Qu XJ, Yuan YX, Tian ZG, Xu WF, Chen MH, Cui SX, Guo Q, Gai R, Makuuchi M, Nakata M, Tang W (2006) Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis. Int J Mol Med 18(4):609\u2013614","journal-title":"Int J Mol Med"},{"issue":"4","key":"559_CR35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4):277\u2013288","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"559_CR36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.cdd.4402028","volume":"14","author":"Q Bao","year":"2007","unstructured":"Bao Q, Shi Y (2007) Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14(1):56\u201365","journal-title":"Cell Death Differ"},{"issue":"2","key":"559_CR37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/0008-5472.448.65.2","volume":"65","author":"T Rothhammer","year":"2005","unstructured":"Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65(2):448\u2013456","journal-title":"Cancer Res"},{"issue":"46","key":"559_CR38","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.1074\/jbc.M207205200","volume":"277","author":"MA Karsdal","year":"2002","unstructured":"Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaisse JM, Foged NT (2002) Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277(46):44061\u201344067","journal-title":"J Biol Chem"},{"issue":"Pt 18","key":"559_CR39","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1242\/jcs.03157","volume":"119","author":"SA Illman","year":"2006","unstructured":"Illman SA, Lehti K, Keski-Oja J, Lohi J (2006) Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18):3856\u20133865","journal-title":"J Cell Sci"},{"issue":"12","key":"559_CR40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603763","volume":"96","author":"ME Polak","year":"2007","unstructured":"Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA (2007) Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96(12):1879\u20131887","journal-title":"Br J Cancer"},{"issue":"53","key":"559_CR41","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1038\/sj.onc.1207103","volume":"22","author":"BC Barnhart","year":"2003","unstructured":"Barnhart BC, Lee JC, Alappat EC, Peter ME (2003) The death effector domain protein family. Oncogene 22(53):8634\u20138644","journal-title":"Oncogene"},{"issue":"16","key":"559_CR42","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/sj.onc.1207513","volume":"23","author":"M Jaattela","year":"2004","unstructured":"Jaattela M (2004) Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23(16):2746\u20132756","journal-title":"Oncogene"},{"issue":"6","key":"559_CR43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ceb.2006.09.006","volume":"18","author":"Y Shi","year":"2006","unstructured":"Shi Y (2006) Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 18(6):677\u2013684","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"559_CR44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri704","volume":"2","author":"L Gorelik","year":"2002","unstructured":"Gorelik L, Flavell RA (2002) Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2(1):46\u201353","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"559_CR45","first-page":"303","volume":"10","author":"LI Gold","year":"1999","unstructured":"Gold LI (1999) The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10(4):303\u2013360","journal-title":"Crit Rev Oncog"},{"key":"559_CR46","unstructured":"Peng Y, Gorelik L, Laouar Y, Li MO, Flavell RA (2006) TGFbeta-mediated immunoregulation. Ernst Schering Res Found Workshop, (56):155\u201360"},{"issue":"2","key":"559_CR47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-2478(03)00002-6","volume":"86","author":"P Conti","year":"2003","unstructured":"Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, Felaco M, Boucher W, Letourneau R, Theoharides TC (2003) IL-10, an inflammatory\/inhibitory cytokine, but not always. Immunol Lett 86(2):123\u2013129","journal-title":"Immunol Lett"},{"issue":"5","key":"559_CR48","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.165.5.2783","volume":"165","author":"FN Lauw","year":"2000","unstructured":"Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T (2000) Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165(5):2783\u20132789","journal-title":"J Immunol"},{"issue":"10","key":"559_CR49","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1128\/JVI.74.10.4729-4737.2000","volume":"74","author":"AD Santin","year":"2000","unstructured":"Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ (2000) Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74(10):4729\u20134737","journal-title":"J Virol"},{"issue":"3","key":"559_CR50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00008390-199806000-00006","volume":"8","author":"D Sharma","year":"1998","unstructured":"Sharma D, Chelvi TP, Kaur J, Ralhan R (1998) Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 8(3):240\u2013244","journal-title":"Melanoma Res"},{"issue":"9","key":"559_CR51","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/jps.20646","volume":"95","author":"HD Han","year":"2006","unstructured":"Han HD, Choi MS, Hwang T, Song CK, Seong H, Kim TW, Choi HS, Shin BC (2006) Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes. J Pharm Sci 95(9):1909\u20131917","journal-title":"J Pharm Sci"},{"issue":"6","key":"559_CR52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/187152006778699095","volume":"6","author":"T Minko","year":"2006","unstructured":"Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M (2006) New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 6(6):537\u2013552","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"559_CR53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00008390-200308000-00009","volume":"13","author":"EM Noorda","year":"2003","unstructured":"Noorda EM, Vrouenraets BC, Nieweg OE, Klaase JM, van der Zee J, Kroon BB (2003) Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 13(4):395\u2013399","journal-title":"Melanoma Res"},{"issue":"4B","key":"559_CR54","first-page":"2891","volume":"17","author":"HI Robins","year":"1997","unstructured":"Robins HI, D\u2019Oleire F, Grosen E, Spriggs D (1997) Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease. Anticancer Res 17(4B):2891\u20132894","journal-title":"Anticancer Res"},{"issue":"2","key":"559_CR55","first-page":"443","volume":"30","author":"E Pagani","year":"2007","unstructured":"Pagani E, Falcinelli S, Pepponi R, Turriziani M, Caporaso P, Caporali S, Bonmassar E, D\u2019Atri S (2007) Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. Int J Oncol 30(2):443\u2013451","journal-title":"Int J Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-008-0559-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0559-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:27:49Z","timestamp":1684470469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-008-0559-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,11]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s00262-008-0559-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,11]]}}}